Adjuvant chemotherapy is associated with improved @entity1349 in pelvic node-positive XXXX after lymph node dissection: A multi-institutional study.

@entity1 @entity957 @entity5 @entity1349
OBJECTIVES: We determined whether adjuvant chemotherapy (AC) would be associated with improved survival after lymph node dissection (LND) for @entity1 with @entity5 ( @entity5 ) who have positive pelvic lymph nodes (PPLNs). METHODS: We retrospectively identified @entity1 across 4 centers with @entity957 who underwent LND from 1978 to 2013 and were found to have PPLNs. @entity1 who received chemotherapy before surgery or in the presence of recurrent disease were excluded. Cox regression was used to evaluate the association of AC with @entity1349 ( @entity1349 ), which was estimated using the Kaplan-Meier method. Differences in @entity1349 were determined with the log-rank test. RESULTS: During the study period, 141 @entity1 who underwent LND for @entity5 had PPLNs, and 84 of them met inclusion criteria. Median number of PPLNs was 2 (interquartile range [IQR]: 4-7), with 10% of cases occurring bilaterally and 55% having pelvic extranodal extension. AC was used in 36 (43%) @entity1 . @entity1 who received AC were younger (P = 0.014), had less-aggressive @entity5 pathology (P<0.01), were less likely to receive adjuvant radiation (P<0.01), had less bilateral inguinal disease (P = 0.019), and had more inguinal extranodal extension (P = 0.042). Median follow-up was 12.1 months. Estimated median @entity1349 was 21.7 months (IQR: 11.8-104) in @entity1 who received AC vs. 10.1 (IQR: 5.6-48.1) in those who did not (P = 0.048). AC was independently associated with improved @entity1349 on multivariate analysis (hazard ratio: 0.40; 95% CI: 0.19-0.87; P = 0.021). CONCLUSIONS: AC is associated with improved @entity1349 in @entity1 with @entity5 who have PPLNs after LND. Prospective studies are needed to demonstrate causality.
